Trends in pharmaceutical industry

1

TRENDS IN PHARMACEUTICAL

INDUSTRYBy:Darya Osman HusseinEman Salah AwadMoaz Ahmed Adam

2

OVERVIEW

• Trend:• General development or change in conditions or

practices.

• In pharmacy:• Pharmaceutical growth or development to revolutionize

the health care system.

3

• Advances in pharmaceutical industry generally targeted at improving efficiency of drug delivery, decreasing cost and improving bioavailability

4

BIOSIMILARS

• A.K.A. follow-on biologic or subsequent entry biologic

• A medical product which is almost an identical copy of an original product manufactured by a different company

• Same idea as the “generic” type drugs but related to biological products (e.g. monoclonal antibodies, colony stimulating factors, etc.)

5

6

• Issues may arise from several aspects:

1. It is difficult and costly to recreate biologics because the complex proteins are derived from living organisms that are genetically modified

2. Every biological (or biopharmaceutical products) displays a certain degree of variability, even between different batches of the same product, which is due to the inherent variability of the biological expression system and the manufacturing process

7

3. It is currently tougher to get a biosimilar product past FDA regulators than their counterparts

4. Medical community concerned with complications, naming and licensing guidelines

8

• Use of biosimilars may allow for 20-30% cheaper versions of biologic drugs therefore research into them is currently underway

9

DIGITAL PHARMA

• Technological innovation allow patients to monitory their health and symptoms outside the clinical environment

• The importance of ‘beyond pill’ services allow better catering to patients needs

• ‘Digital medicine’ brought on various advances in drug composition

10

• Example is the anti-psychotic drug Abilify (Aripiprazole) includes an ingestible sensor attached to pill

• Allows for monitoring of patient adherence to drug and will therefore allow for better clinical outcome

• Digital collaborations between pharma and tech are becoming more common everyday

11

12

ADVANCEMENT IN DRUG DELIVERY

• Include research and development in various types of drug delivery and routes of administration

13

DEVELOPMENTS IN INJECTABLE DELIVERY

• Injectable agents currently outnumber oral agents by approximately 30%

• In general this route considered as an unpleasant experience by many patients

• Generally tailoring involves consideration into two parameters:• Formulation• Device

14

•Delivery device• Smaller needle• auto injectors

15

16

MICRO ELECTRO MECHANICAL SYSTEM (MEMS)

• Preloaded with lyophilized/freeze dried drug in silicone rubber reservoir

• Drug delivered by processing device against skin for few seconds

• Drug pushed through microneedles into skin and absorbed via interstitial fluids into the bloodstream

17

18

•Formulation alteration :

1. Can reduce frequency of administration

2. Reduce volume needed for injection

3. Reduce side effects (e.g. immunogenicity)

19

PEGYLATING

• Significantly increases in vivo half life• Prevents attack by proteolytic enzymes

20

HEPAROSAN CONJUGATES

• Heparosan polysaccharide sequences make up about 30% of the body's heparin sulfate (found in most cells/tissues) and heparin

• has no heparin sulfate or heparin-like biological activity.

21

• By attaching synthetic heparosan to a drug molecule, an extended-release formulation similar to PEGylating can be created but with much less risk of an immunogenic reaction.

• Additionally, the half-life of a drug-heparosan conjugate can be easily customized by simply altering the defined size of the polymer

22

MUCOSIS VACCINES

• Dutch biotechnology company developing trans mucosal administration of vaccines• Method is more patient friendly and give

superior immune response to vaccine

23

24

• Theory is that vaccine is given via same route as pathogen invasion resulting in response similar to natural immune response

• Mucosally administered vaccines also elicit systemic and local immune response translating to improved protection.

25

E.g. SynGEM – vaccine against RSV currently in preclinical testing

26

TARGETED DRUG DELIVERY

• Improving delivery involves lower cost than discovery of new molecule

• Increase commercial opportunity by protecting product from “me too” drugs

• Allows branded drugs to be distinguished from generic competition

27

ADVANCED COATING TECHNOLOGY

• Allow for delivery of targeted medications causing reduction of drug degradation, systemic side effects and more effective treatment • E.g. Multi Matrix MMX for

IBD• Uses pH resistant coating to

delay release of drug until reaches lower digestive tract

• Provides topical treatment at site of inflammation

28

29

LIPOSOMAL DRUG DELIVERY

• Liposomal packaged drugs exhibit reduced toxicity and enhanced effectiveness

• Altered pharmacokinetics also allow for drug targeting and accumulation at disease sites reducing distribution

• Allows for sensitive tissue target delivery of drugs

30

31

MONOCLONAL ANTIBODIES

• Act by binding to a specific antigen and inducing immunological response

• May prove to be very useful in targeting cancer cells while reducing harm to normal body cells

32

NANOPARTICLE BASED DRUG DELIVERY

• Drug can be targeted to a precise location

• Results in increased effectiveness and reduced chance of possible side effects

• Nanocariers include:• Nanoparticles• Nano tubules • Nano shells

33

SIGNIFICANT ADVANCES IN NANO DELIVERY

1. One dose a day Cipro using nanotechnology

2. Tumor targeted Taxol using nanoparticles

3. Improved ophthalmic delivery using smart hydrogel nanoparticles

4. Oral insulin using nanoparticle carriers

34

CHALLENGES

1. Protect drugs from biological degradation

2. Effective targeting

3. Patient compliance

4. Cost effectiveness

5. Product life extension

35

CARBON NANOTUBE

• Adept at entering the nuclei of cells and may one day be used to deliver drugs and vaccines

• So far only able to carry a small peptide into the nuclei of fibroblast cells

• Potential use in new anti-cancer treatments, gene therapies and vaccines

36

GOLD NANOPARTICLES

• Used in cancer chemotherapy and act via free radical generation

37

NANOERYTHROSOMES

• Resealed erythrocytes that carry protein, enzymes and macromolecules

• Used in treatment of liver, tumor and parasitic disease.

• Biocompatible (b/c use patients own erythrocytes), nontoxic and large space available for drug due to anucleation

38

39

DENDRIMER

• Dendritic macromolecules (highly branched) which are used to encapsulated individual drug molecules (unimolecular Nano capsule)

• Can also act as attachment ‘hubs’ for large numbers of drug molecules attached via covalent bond

• E.g. anticancer agents 5-fluorouracil with polyaminoamine dendrimers

40

41

MODIFIED BUCKY BALL

• Deliver radioactive atoms to cancerous cells

• Radiation is transferred within the ball therefore minimizing damage to healthy tissue

42

NANO-ROBOTS

• Used in treatment of cancer

43

• Designed to find and destroy only cancer cells

• Healthy cells remain unharmed

44

FUTURE OPPORTUNITIES AND CHALLENGES

1. Nano-drug delivery systems that deliver large but highly localized quantities of drugs to specific areas to be released in controlled ways

2. Controllable release profiles, especially for sensitive drugs;

3. Materials for nanoparticles that are biocompatible and biodegradable;

4. Architectures / structures, such as biomimetic polymers, nanotubes

45

5.  Functions (active drug targeting, on-command delivery, intelligent drug release devices/ bioresponsive triggered systems, self-regulated delivery systems, systems interacting with the body, smart delivery)

6. Virus-like systems for intracellular delivery

7. Nanoparticles for tissue engineering; e.g. for the delivery of cytokines to control cellular growth and differentiation, and stimulate regeneration; or for coating implants with nanoparticles in biodegradable polymer layers for sustained release

8. Advanced polymeric carriers for the delivery of therapeutic peptide/proteins (biopharmaceutics),

46